We provide a GLP-validated, end-to-end service for measuring endogenous glucose production (EGP) and peripheral glucose uptake (PGU) in clinical glucose clamp studies using the stable isotope tracer [6,6-2H2]glucose.
Endogenous glucose production (EGP) is the rate at which glucose enters the circulation from the body’s own sources. It originates mainly from the liver (glycogenolysis and gluconeogenesis), with a smaller renal contribution, and is expressed in mg/kg/min. Insulin suppresses EGP; glucagon stimulates it.
Peripheral glucose uptake (PGU), also referred to as glucose disposal or rate of disappearance (Rd), is the rate at which glucose leaves the plasma and is taken up by tissues – under insulin stimulation predominantly skeletal muscle and adipose tissue.
In a glucose clamp, the glucose infusion rate (GIR) only reflects the net effect of a drug: at steady state, PGU equals EGP plus GIR. A change in GIR can therefore result from altered hepatic glucose output, altered peripheral uptake, or both. Only a tracer clamp separates the two and shows where a compound acts.
Glucagon acts on hepatocytes via the glucagon receptor (GCGR) and stimulates glycogenolysis and gluconeogenesis; it also increases hepatic lipid oxidation and energy expenditure. GLP-1 receptor (GLP-1R) agonism, in contrast, enhances glucose-dependent insulin secretion and suppresses endogenous glucagon. Molecules that combine both activities – GLP-1R/GCGR dual agonists and GIPR/GLP-1R/GCGR triple agonists – therefore exert opposing forces on hepatic glucose output.
The net effect on EGP depends on the GLP-1R : GCGR potency ratio, the dose, the time course of exposure and the metabolic state of the study population. Tracer-derived EGP answers questions that glucose and GIR data alone cannot:
With a growing number of GCGR-targeting compounds in clinical development, EGP is becoming a central comparator parameter for demonstrating a differentiated pharmacodynamic profile.
| Compound (INN) | Receptor profile | Development status* |
|---|---|---|
| mazdutide | GLP-1R / GCGR dual agonist | Approved (China) |
| survodutide | GLP-1R / GCGR dual agonist | Phase 3 |
| retatrutide | GIPR / GLP-1R / GCGR triple agonist | Phase 3 |
| pemvidutide | GLP-1R / GCGR dual agonist | Phase 3 (MASH) |
| efinopegdutide | GLP-1R / GCGR dual agonist | Phase 2b (MASH) |
| efocipegtrutide | GIPR / GLP-1R / GCGR triple agonist | Phase 2b (MASH) |
| dasiglucagon | GCGR agonist (glucagon analogue) | Approved (severe hypoglycaemia) |
| semaglutide | GLP-1R agonist – no GCGR activity | Approved – incretin benchmark |
| tirzepatide | GIPR / GLP-1R dual agonist – no GCGR activity | Approved – incretin benchmark |
*Selected compounds for scientific orientation; status as of October 2026 based on public sources. No affiliation with or endorsement by the respective developers is implied.
The method is based on isotope dilution. A primed-continuous intravenous infusion of [6,6-2H2]glucose establishes a stable plasma tracer enrichment. Glucose released from endogenous sources is unlabelled and dilutes the tracer; the degree of dilution is used to calculate the rate of glucose appearance (Ra). During the clamp, the exogenous glucose infusate is enriched with the same tracer (“hot GINF”), which keeps plasma enrichment stable while insulin and the study drug act, and minimises non-steady-state errors.
Blood samples are taken at predefined time points, for example at the end of each glucose or insulin plateau. Tracer enrichment (tracer-to-tracee ratio) is determined by gas chromatography–mass spectrometry (GC-MS). EGP and PGU are then calculated with Steele’s non-steady-state equations as modified by Powrie et al. for labelled glucose infusates: EGP is obtained as total Ra minus the exogenous glucose infusion, and PGU corresponds to Rd.
[6,6-2H2]glucose is a stable, non-radioactive tracer with minimal label recycling. It is the established reference tracer for glucose turnover studies and can be used repeatedly in the same participant, which makes it well suited for crossover and dose-response designs.
All steps are available from one provider and one data chain. The modules can also be combined according to the needs of the study.
Provision of GMP-certified [6,6-2H2]glucose infusion solutions for clinical use, including tracer-enriched glucose infusates for the clamp by the university hospital pharmacy.
Planning and conduct of glucose clamp studies with the CTU at Med Uni Graz: hyperinsulinaemic-euglycaemic, isoglycaemic, multi-step and stepwise hypoglycaemic clamps, with tracer priming, infusion and sampling protocols.
GC-MS determination of [6,6-2H2]glucose enrichment (tracer-to-tracee ratio) in clinical plasma samples under GLP-validated conditions.
GCP-compliant, audit-trailed data capture, cleaning and transfer of clamp, tracer and laboratory data.
Calculation of EGP and PGU and derived endpoints with Steele’s non-steady-state equations (Powrie modification), statistical analyses, and reports ready for regulatory submission.
Typical applications include single-dose and steady-state PK/PD studies, dose-response studies, randomised crossover and parallel-group comparisons, head-to-head studies against reference compounds, and studies of counter-regulation and hypoglycaemia safety. Studies can be conducted in healthy volunteers and in people with obesity, type 1 diabetes or type 2 diabetes.
Tracer-based EGP/PGU methods are well established in academic research, but are rarely available as a validated routine service. JOANNEUM RESEARCH HEALTH has transferred the method into standardised routine processes and validated the bioanalysis and the calculation of EGP and PGU to GLP level. To our knowledge, we are the only provider offering tracer-based EGP/PGU determination under GLP-validated conditions. Tracer infusion solutions are GMP-certified; clinical conduct and data management follow GCP.
| Service | Stable isotope tracer clamp for the quantification of EGP and PGU |
|---|---|
| Provider | JOANNEUM RESEARCH HEALTH – Institute for Biomedical Research and Technologies, Graz, Austria |
| Tracer | [6,6-2H2]glucose (stable, non-radioactive), supplied as GMP-certified infusion solutions |
| Clamp designs | Hyperinsulinaemic-euglycaemic, isoglycaemic, single- or multi-step insulin clamps, stepwise hypoglycaemic clamps |
| Bioanalysis | GC-MS determination of tracer enrichment (tracer-to-tracee ratio), GLP-validated |
| Kinetic model | Steele’s non-steady-state equations, modified for tracer-enriched glucose infusates; GLP-validated calculation |
| Main outputs | EGP (Ra), PGU (Rd), % EGP suppression, AOCEGP, AUCPGU, glucose infusion rate (GIR) endpoints |
| Quality framework | GMP (tracer), GCP (clinical conduct, data management), GLP (bioanalysis, EGP/PGU calculation) |
| Populations | Healthy volunteers; people with obesity, type 1 or type 2 diabetes |
| Experience | Tracer clamp studies published since 2005 |
Get in touch with us